Page last updated: 2024-08-22

camptothecin and Leukemia, Myelomonocytic, Chronic

camptothecin has been researched along with Leukemia, Myelomonocytic, Chronic in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (66.67)	18.2507
2000's	1 (33.33)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cortes, J; Faderl, S; Giles, F; Jabbour, E; Kantarjian, H; O'Brien, S; Pierce, S; Quintas-Cardama, A; Ravandi, F; Shan, J; Verstovsek, S	1
Abbruzzese, JL; al-Bitar, M; Andreeff, M; Arbuck, S; Beran, M; Estey, E; Kantarjian, H; Keating, M; Koller, C; Moore, M; O'Brien, S; Pierce, S	1

Trials

2 trial(s) available for camptothecin and Leukemia, Myelomonocytic, Chronic

Article	Year
Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia. Cancer, 2006, Oct-01, Volume: 107, Issue:7 Topics: Administration, Oral; Adult; Aged; Animals; Antineoplastic Agents; Camptothecin; Female; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Topoisomerase I Inhibitors; Treatment Outcome	2006
Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood, 1996, Oct-01, Volume: 88, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Diarrhea; Female; Fever; Follow-Up Studies; Genes, ras; Humans; Leukemia, Myelomonocytic, Chronic; Life Tables; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Remission Induction; Stomatitis; Survival Analysis; Survival Rate; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome	1996

Article

Year

Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia.

Cancer, 2006, Oct-01, Volume: 107, Issue:7

Topics: Administration, Oral; Adult; Aged; Animals; Antineoplastic Agents; Camptothecin; Female; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Topoisomerase I Inhibitors; Treatment Outcome

2006

Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.

Blood, 1996, Oct-01, Volume: 88, Issue:7

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Diarrhea; Female; Fever; Follow-Up Studies; Genes, ras; Humans; Leukemia, Myelomonocytic, Chronic; Life Tables; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Remission Induction; Stomatitis; Survival Analysis; Survival Rate; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome

1996

Other Studies

1 other study(ies) available for camptothecin and Leukemia, Myelomonocytic, Chronic

Article	Year
Hycamtin achieves promising results in study of patients with leukemia. Oncology (Williston Park, N.Y.), 1996, Volume: 10, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Ovarian Neoplasms; Remission Induction; Topotecan	1996